• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在使用特定抗精神病药物治疗且以阴性或思维紊乱症状突出的精神分裂症门诊患者中,PANSS 阴性症状因子评分的可靠性、有效性和变化检测能力。

Reliability, validity and ability to detect change of the PANSS negative symptom factor score in outpatients with schizophrenia on select antipsychotics and with prominent negative or disorganized thought symptoms.

机构信息

Roche Products Ltd., 6 Falcon Way, Shire Park, Welwyn Garden City AL7 1TW, United Kingdom.

F. Hoffmann-La Roche Ltd., Basel, Switzerland.

出版信息

Psychiatry Res. 2014 Aug 15;218(1-2):219-24. doi: 10.1016/j.psychres.2014.04.009. Epub 2014 Apr 13.

DOI:10.1016/j.psychres.2014.04.009
PMID:24809242
Abstract

The PANSS is a valid instrument assessing schizophrenia symptom severity. Analyses have identified a five-factor solution. The negative symptom factor (NSFS) is robust, having been replicated in multiple analyses. The score has superior content validity versus the negative subscale. Aspects of validity in patients with predominant negative symptoms have yet to be established. The present data are from a Phase IIb study of add-on bitopertin therapy in schizophrenia outpatients with prominent negative or disorganized thought symptoms treated with antipsychotics. Analyses were conducted to evaluate reliability, validity and sensitivity to change. Test-retest screening to baseline was high (ICC=0.93). This was maintained in-study, for patients with no change in CGI negative symptom severity (CGI-S-N). Internal consistency at baseline was adequate (α=0.71) and increased at later assessments. Pearson correlation at baseline showed a good association between NSFS and CGI-S-N (0.63), but not overall CGI-S (0.31). Association with PSP at baseline was moderate (-0.39) and for change at Week eight good (-0.65). NSFS responders (≥20% improvement) at Week eight showed a significant improvement in function. The analyses demonstrated reliability, validity and ability to detect change of the NSFS, in schizophrenia patients with prominent negative or disorganized thought symptoms.

摘要

PANSS 是一种评估精神分裂症症状严重程度的有效工具。分析已经确定了一个五因素解决方案。阴性症状因子(NSFS)是稳健的,在多项分析中得到了验证。与阴性子量表相比,该评分具有更高的内容效度。在以阴性症状为主的患者中,其有效性的各个方面尚未得到确定。本数据来自于一项针对伴有突出阴性或思维紊乱症状的精神分裂症门诊患者的附加双氢麦角隐亭治疗的 IIb 期研究,这些患者接受了抗精神病药物治疗。进行了分析以评估可靠性、有效性和对变化的敏感性。从测试到测试的筛选到基线很高(ICC=0.93)。在研究期间保持不变,对于 CGI 阴性症状严重程度无变化的患者(CGI-S-N)。基线时的内部一致性足够(α=0.71),并且在以后的评估中增加。基线时 NSFS 与 CGI-S-N 之间存在良好的相关性(0.63),但与总体 CGI-S 相关性不高(0.31)。与 PSP 基线的相关性为中度(-0.39),而第八周的变化相关性良好(-0.65)。第八周时 NSFS 应答者(≥20%改善)的功能显著改善。这些分析表明,在伴有突出阴性或思维紊乱症状的精神分裂症患者中,NSFS 具有可靠性、有效性和检测变化的能力。

相似文献

1
Reliability, validity and ability to detect change of the PANSS negative symptom factor score in outpatients with schizophrenia on select antipsychotics and with prominent negative or disorganized thought symptoms.在使用特定抗精神病药物治疗且以阴性或思维紊乱症状突出的精神分裂症门诊患者中,PANSS 阴性症状因子评分的可靠性、有效性和变化检测能力。
Psychiatry Res. 2014 Aug 15;218(1-2):219-24. doi: 10.1016/j.psychres.2014.04.009. Epub 2014 Apr 13.
2
Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia.精神分裂症急性症状患者中临床医生评定的个人和社会表现量表的信度、效度及检测变化的能力。
Curr Med Res Opin. 2009 Feb;25(2):325-38. doi: 10.1185/03007990802611919.
3
Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme.在使用抗精神病药物治疗但症状控制欠佳的精神分裂症患者中,辅助使用氨磺必利与安慰剂的疗效和安全性:来自SearchLyte临床试验项目三项3期随机、双盲、平行组、安慰剂对照、多中心研究的结果。
Lancet Psychiatry. 2016 Dec;3(12):1115-1128. doi: 10.1016/S2215-0366(16)30344-3. Epub 2016 Nov 2.
4
A double-blind randomized study assessing safety and efficacy following one-year adjunctive treatment with bitopertin, a glycine reuptake inhibitor, in Japanese patients with schizophrenia.一项双盲随机研究,评估甘氨酸再摄取抑制剂比特肽对日本精神分裂症患者进行一年辅助治疗后的安全性和有效性。
BMC Psychiatry. 2016 Mar 15;16:66. doi: 10.1186/s12888-016-0778-9.
5
Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.齐拉西酮和阿立哌唑有效治疗精神分裂症的阴性症状:一项为期12周的双盲研究结果。 你提供的原文中药物名称有误,正确的应该是齐拉西酮(Ziprasidone)和阿立哌唑(Aripiprazole),我按照正确的药物名称进行了翻译。若按照你给定的原文“Ziprasidone and amisulpride”翻译,译文为“齐拉西酮和氨磺必利有效治疗精神分裂症的阴性症状:一项为期12周的双盲研究结果” 。
Int Clin Psychopharmacol. 2006 May;21(3):143-51. doi: 10.1097/01.yic.0000182121.59296.70.
6
Bitopertin in Negative Symptoms of Schizophrenia-Results From the Phase III FlashLyte and DayLyte Studies.比哌立登治疗精神分裂症阴性症状的疗效-III 期 FlashLyte 和 DayLyte 研究结果。
Biol Psychiatry. 2017 Jul 1;82(1):8-16. doi: 10.1016/j.biopsych.2016.11.014. Epub 2016 Dec 15.
7
Linking PANSS negative symptom scores with the Clinical Global Impressions Scale: understanding negative symptom scores in schizophrenia.将 PANSS 阴性症状评分与临床总体印象量表相联系:理解精神分裂症中的阴性症状评分。
Neuropsychopharmacology. 2019 Aug;44(9):1589-1596. doi: 10.1038/s41386-019-0363-2. Epub 2019 Mar 5.
8
Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study.在常规临床实践中,使用抗精神病药物治疗精神分裂症谱系障碍门诊患者的阴性症状患病率:CLAMORS 研究的结果。
J Clin Psychiatry. 2010 Mar;71(3):280-6. doi: 10.4088/JCP.08m04250yel. Epub 2009 Nov 3.
9
Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: Pooled analyses from 3 phase II/III studies.卡利拉嗪在精神分裂症急性加重期患者多个症状领域的疗效:来自 3 项 2/3 期研究的汇总分析。
Eur Neuropsychopharmacol. 2019 Jan;29(1):127-136. doi: 10.1016/j.euroneuro.2018.10.008. Epub 2018 Nov 20.
10
The efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors.卡利拉嗪治疗精神分裂症阴性症状的疗效:阳性和阴性症状量表(PANSS)各单项和因子的事后分析。
Eur Psychiatry. 2019 May;58:1-9. doi: 10.1016/j.eurpsy.2019.01.015. Epub 2019 Feb 7.

引用本文的文献

1
The Association between Self-Reported Self-Disturbance Phenomena and Personal Recovery in Patients with a Schizophrenia Spectrum Disorder, Siblings and Controls.精神分裂症谱系障碍患者、其兄弟姐妹及对照组中自我报告的自我干扰现象与个人康复之间的关联
Psychopathology. 2025 May 28:1-22. doi: 10.1159/000546557.
2
COSMIN systematic review and meta-analysis of the measurement properties of the Positive and Negative Syndrome Scale (PANSS).COSMIN对阳性和阴性症状量表(PANSS)测量属性的系统评价与Meta分析。
EClinicalMedicine. 2025 Apr 11;82:103155. doi: 10.1016/j.eclinm.2025.103155. eCollection 2025 Apr.
3
Cognitive effects of brief and intensive neurofeedback treatment in schizophrenia: a single center pilot study.
简短密集型神经反馈治疗对精神分裂症的认知影响:一项单中心试点研究。
AIMS Neurosci. 2024 Sep 9;11(3):341-351. doi: 10.3934/Neuroscience.2024021. eCollection 2024.
4
A generalisability theory approach to quantifying changes in psychopathology among ultra-high-risk individuals for psychosis.一种用于量化精神病超高风险个体精神病理学变化的概化理论方法。
Schizophrenia (Heidelb). 2024 Oct 4;10(1):87. doi: 10.1038/s41537-024-00503-y.
5
Remote Assessment of Negative Symptoms of Schizophrenia.精神分裂症阴性症状的远程评估
Schizophr Bull Open. 2023 Jan 26;4(1):sgad001. doi: 10.1093/schizbullopen/sgad001. eCollection 2023 Jan.
6
Systematic Literature Review of Studies Reporting Measures of Functional Outcome or Quality of Life in People with Negative Symptoms of Schizophrenia.关于报告精神分裂症阴性症状患者功能结局或生活质量测量指标的研究的系统文献综述
Patient Relat Outcome Meas. 2024 Jun 17;15:199-217. doi: 10.2147/PROM.S454845. eCollection 2024.
7
Impacts of a Self-directed Social Resources Study Program on Negative Symptoms and Quality of Life in Schizophrenia Outpatients: A Randomized Controlled Trial.一项自我导向的社会资源研究项目对精神分裂症门诊患者阴性症状和生活质量的影响:一项随机对照试验。
Kobe J Med Sci. 2024 Apr 1;70(1):E15-E21. doi: 10.24546/0100488377.
8
Impact of conspiracist ideation and psychotic-like experiences in patients with schizophrenia during the COVID-19 crisis.在 COVID-19 危机期间,精神分裂症患者的阴谋论观念和类似精神病的体验的影响。
J Psychiatr Res. 2022 Feb;146:135-148. doi: 10.1016/j.jpsychires.2021.12.022. Epub 2021 Dec 24.
9
Directly and Indirectly Targeting the Glycine Modulatory Site to Modulate NMDA Receptor Function to Address Unmet Medical Needs of Patients With Schizophrenia.直接和间接靶向甘氨酸调节位点以调节NMDA受体功能,满足精神分裂症患者未被满足的医疗需求。
Front Psychiatry. 2021 Oct 1;12:742058. doi: 10.3389/fpsyt.2021.742058. eCollection 2021.
10
EPA guidance on assessment of negative symptoms in schizophrenia.美国环保署关于精神分裂症阴性症状评估的指南。
Eur Psychiatry. 2021 Feb 18;64(1):e23. doi: 10.1192/j.eurpsy.2021.11.